Biologics appear to be safe in patients with psoriasis who are seropositive for viral hepatitis, but not enough data are available, especially regarding anti-IL-17 and anti-IL-23 drugs. |
Drug resistance due to the use of prophylactic antivirals is an increasing concern. |
In our experience, despite not receiving prophylaxis, no patient had evidence of viral reactivation during the treatment, supporting the high safety profiles of biologic drugs. |
Biologics, including anti-IL-17 and anti-IL-23, appear to be a safe therapeutic option in patients with serological evidence of viral hepatitis with a follow-up of at least 52 weeks. |
Longer studies with larger cohorts of patients are needed to further assess this subject. |
Introduction
Methods
Results
Patient number | Sex | Age group | Comorbidities | HbsAg (mIU/mL) | HbsAb | HbcAb | HBV-DNA | Biologic therapies | Follow-up duration (weeks) | PASI baseline | PASI at last observation |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 40–44 | / | 256.66 | 19.19 | Negative | Undetectable | Risankizumab | 104 | 16 | 0 |
2 | M | 55–69 | DM2, hypertension | Negative | Positive | Positive | Undetectable | Ustekinumab | 52 | 12 | 5 |
3 | M | 65–69 | DM2, NASH | Negative | Negative | Positive | Undetectable | Risankizumab | 52 | 10 | 1 |
4 | M | 50–54 | HCVab+ | Negative | < 1 | Positive | Undetectable | Risankizumab | 52 | 15 | 0 |
5 | M | 55–59 | Hypertension, NAFLD | Negative | Negative | Positive | Undetectable | Tildrakizumab | 52 | 25.5 | 0 |
6 | F | 55–59 | Hypertension | Negative | Negative | Positive | Undetectable | Risankizumab | 52 | 12 | 0 |
7 | M | 50–54 | Metabolic syndrome | Positive | Negative | Positive | Undetectable | Risankizumab | 52 | 20 | 10 |
8 | M | 65–69 | Previous bladder carcinoma | Negative | Negative | Positive | Undetectable | Etanercept, risankizumab | 208 | 32 | 0 |
9 | M | 55–59 | PsA | Negative | Negative | Positive | Undetectable | Adalimumab, ixekizumab | 208 | 18 | 0 |
10 | M | 55–59 | / | Negative | Negative | Positive | Undetectable | Secukinumab | 104 | 18 | 0.3 |
11 | F | 65–69 | PsA, hypertension | Negative | Negative | Positive | Undetectable | Guselkumab, ixekizumab | 52 | 10 | 1 |
12 | M | 55–59 | Hypercholesterolemia | Negative | 211 | Positive | Undetectable | Tildrakizumab | 52 | 12 | 0 |
13 | F | 70–74 | Hypertension | Negative | Positive | Positive | Undetectable | Risankizumab | 52 | 28 | 0 |
14 | F | 55–59 | Hypertension, NASH | Negative | Positive | Positive | Undetectable | Risankizumab | 88 | 10 | 0 |
15 | M | 70–74 | Hypertension, QuantiFERON positive | Negative | Negative | Positive | Undetectable | Risankizumab | 128 | 15 | 0 |
16 | M | 45–49 | Hypertension, OSAS | Negative | Negative | Positive | Undetectable | Ustekinumab, risankizumab | 140 | 17 | 0 |
17 | M | 60–64 | / | Negative | Positive | Positive | Undetectable | Secukinumab, brodalumab | 128 | 10 | 0 |
Patient number | Sex | Age | Comorbidities | HCV-ab | HCV-RNA | Biologic therapies | Follow-up duration (weeks) | PASI baseline | PASI at last observation |
---|---|---|---|---|---|---|---|---|---|
1 | F | 50–54 | Hypertension, obesity | Positive | Undetectable | Ustekinumab | 220 | 30 | 5 |
2 | M | 50–54 | HBcAb+ | Positive | Undetectable | Risankizumab | 52 | 15 | 0 |
3 | M | 55–59 | Hypertension, CVD | Positive | Undetectable | Ixekizumab | 52 | 18 | 0 |
4 | M | 60–64 | PsA | Positive | Undetectable | Adalimumab, secukinumab, brodalumab | 104 | 10 | 1 |